The aspartic protease cathepsin D (cath-D) is a key mediator of induced-apoptosis and its proteolytic activity has been generally involved in this event. During apoptosis, cath-D is translocated to the cytosol. Because cath-D is one of the lysosomal enzymes that requires a more acidic pH to be proteolytically active relative to the cysteine lysosomal enzymes such as cath-B and -L, it is therefore open to question whether cytosolic cath-D might be able to cleave substrate(s) implicated in the apoptotic cascade. Here, we have investigated the role of wild-type cath-D and its proteolytically inactive counterpart overexpressed by 3Y1-Ad12 cancer cells during chemotherapeutic-induced cytotoxicity and apoptosis, as well as the relevance of cath-D catalytic function. We demonstrate that wild-type or mutated catalytically inactive cath-D strongly enhances chemo-sensitivity and apoptotic response to etoposide. Both wild-type and mutated inactive cath-D are translocated to the cytosol, increasing the release of cytochrome c, the activation of caspases-9 and -3 and the induction of a caspase-dependent apoptosis. In addition, pretreatment of cells with the aspartic protease inhibitor, pepstatin A, does not prevent apoptosis. Interestingly therefore, the stimulatory effect of cath-D on cell death is independent of its catalytic activity. Overall, our results imply that cytosolic cath-D stimulates apoptotic pathways by interacting with a member of the apoptotic machinery rather than by cleaving specific substrate(s).
Introduction
Cathepsin D (cath-D) (EC 3.4.23.5 ) is an ubiquitous lysosomal aspartic protease extensively reported as being an active player in breast cancer (Garcia et al., 1990; Liaudet et al., 1994; Rochefort, 1996; Glondu et al., 2001 Glondu et al., , 2002 Berchem et al., 2002; Laurent-Matha et al., 2005) . More recently, cath-D has also been discovered as a key mediator of apoptosis induced by many apoptotic agents such as IFN-gamma, Fas/APO, TNF-alpha (Deiss et al., 1996) , oxidative stress (Roberg and Ö llinger, 1998; Ö llinger, 2000; Kagedal et al., 2001; Roberg, 2001; Takuma et al., 2003) , adriamycin and etoposide (Wu et al., 1998; Emert-Sedlak et al., 2005) , as well as staurosporine (Johansson et al., 2003) . The role of cath-D in apoptosis has been linked to the lysosomal release of mature 34 kDa cath-D into the cytosol leading in turn to the mitochondrial release of cytochrome c (cyt c) into the cytosol (Roberg and Ö llinger, 1998; Ö llinger, 2000; Kagedal et al., 2001; Roberg, 2001; Roberg et al., 2002; Johansson et al., 2003) , activation of pro-caspases (Ö llinger, 2000; Roberg et al., 2002; Johansson et al., 2003; Heinrich et al., 2004) , in vitro cleavage of Bid at pH 6.2 (Heinrich et al., 2004) , or Bax activation independently of Bid cleavage (Bide`re et al., 2003) .
Numerous studies have shown that pepstatin A, an aspartic protease inhibitor, could partially delay apoptosis induced by IFN-gamma and Fas/APO (Deiss et al., 1996) , staurosporine (Terman et al., 2002; Bide`re et al., 2003; Johansson et al., 2003) , TNF-alpha (Deiss et al., 1996; Demoz et al., 2002; Heinrich et al., 2004) , serum deprivation (Shibata et al., 1998) , oxidative stress (Ö llinger, 2000; Kagedal et al., 2001; Roberg, 2001; Takuma et al., 2003) or even when cath-D was microinjected (Roberg et al., 2002) . These authors have thus concluded that cath-D plays a key role in apoptosis mediated via its catalytic activity.
However, cath-D is one of the lysosomal enzymes that requires a more acidic pH to be proteolytically active, relative to the cysteine lysosomal enzymes such as cath-B and -L. Acidification of the cytosol down to pH values of about 6.7-7 is a well-documented phenomenon in apoptosis (Gottlieb et al., 1996; Matsuyama et al, 2000) . In vitro cath-D can cleave its substrates up to a pH of 6.2, but not above (Capony et al., 1987) . Hence, it is predictable that the proteolytic activity of cytosolic cath-D would be drastically impaired under adverse pH conditions unfavourable for its catalytic function. It is therefore open to question whether cath-D might be able to cleave cytosolic substrate(s) implicated in the apoptotic cascade. In accordance with this proposal, it was recently described that pepstatin A did not prevent the death of cells treated by etoposide, doxorubicin, anti-CD95 or TNF-alpha (Demoz et al., 2002; Tardy et al., 2003; Emert-Sedlak et al., 2005) . Furthermore, pepstatin A did not suppress Bid cleavage or procaspases-9 and -3 activation by photodynamic therapy in murine hepatoma cells (Reiners et al., 2002) . Finally, deficiency in cath-D activity did not alter cell death induction in CONCL fibroblasts (Tardy et al., 2003) . In this latter study, Tardy et al. (2003) discussed the possibility that catalytically inactive cath-D might well be implicated in apoptosis.
Results and discussion
In this paper, we have investigated the role of wild-type cath-D and its proteolytically inactive counterpart overexpressed by cancer cells in chemotherapeuticinduced cytotoxicity and apoptosis, and more precisely the relevance of cath-D catalytic function. We used the 3Y1-Ad12 cancer cell line -stably transfected with either wild-type cath-D or catalytically inactive (Figure 1 ). Similar data were obtained with the DNA intercalator doxorubicin and the anti-metabolite 5-fluorouracil (data not shown). We, therefore, conclude that cath-D overexpressed by cancer cells increases their cytotoxic responses to chemotherapeutic agents independently of its catalytic activity. As many reported clinical studies have associated cath-D overexpression with an increased risk of clinical metastasis and shorter survival in breast cancer patients (Rochefort, 1996; Westley and May, 1996; Ferrandina et al., 1997; Foekens et al., 1999) , our results appear to support strongly the hypothesis that patients with breast cancer overexpressing cath-D might be more receptive to chemotherapeutic treatment. Cathepsin-D has been described as being readily translocated to the cytosol in response to various apoptotic stimuli (Kagedal et al., 2001; Roberg, 2001; Bide`re et al., 2003; Johansson et al., 2003; Heinrich et al., 2004; Emert-Sedlak et al., 2005) . We, therefore, investigated the subcellular distribution of wild-type and (Figure 3b) . The cytosol-lysosome pH gradient seemed to be preserved in etoposide-treated cells because LysoTracker-Red, an acidic organellespecific probe, still accumulated in granular cellular structures (data not shown) Werneburg et al. (2002) .
Cytochrome c has been shown to be released from mitochondria to the cytosol during etoposide-induced apoptosis (Sawada et al., 2000) . A typical mitochondrial pattern was observed by immunofluorescence analysis of cyt c in untreated control, cath-D or (b, c, e, f) . Cells were incubated first with anti-human cath-D M1G8 mouse monoclonal antibody at 2.5 mg/ml (Cis Bio International, Gif-sur-Yvette, France) followed by a RITC-conjugated goat anti-mouse antibody (dilution 1/50; Immunotech), as previously described (Liaudet et al., 1994) . Bars, 7.4 mm. cath-D (bottom panel) in cytosols extracted from cells either exposed to 10 mM etoposide for indicated periods of time or left untreated. Cytosol was extracted using 20 mg/ml and 45 mg/ml digitonin (Fluka) for cath-D and D231N cath-D cells, respectively, for 10 min as previously described (Johansson et al., 2003) . Cath-D immunoblotting was performed using an anti-human cath-D monoclonal mouse antibody (1 mg/ml; #610800, BD PharMingen) followed by an anti-mouse peroxidase-conjugated antibody (dilution 1/4000; Amersham Biosciences). An anti-beta-actin (Sigma) was used as a control for protein loading. cath-D cells exposed to 10 mM etoposide, translocation of cyt c from the mitochondria into the cytosol was observed (Figure 4a ). These results indicate that cath-D overexpressed by cancer cells contributes to mitochondrial cyt c release in etoposide-treated cells independently of its catalytic function.
We then investigated whether cath-D plays a role in the activation of caspases-9 and -3 as these caspases have been shown to play a pivotal role in etoposideinduced apoptosis (Sawada et al., 2000) . As illustrated in Figure 4b , caspases-9 and -3 were both activated in cath-D and (Figure 5a) . In parallel experiments, we verified that Z-VAD-FMK efficiently inhibited caspase-3 activation in our cells (Figure 5b) .
Overall, our study has demonstrated that the overexpression of both wild-type and D231 cath-D by cancer cells can enhance the cytotoxicity of chemotherapeutic agents and their apoptotic response to etoposide treatment. Both active and inactive cath-D are rapidly released into the cytosol after etoposide treatment and this phenomenon is closely associated with cyt c release and caspase-dependent apoptotic events.
The function of cath-D in apoptosis is not yet fully understood and needs further investigation. Cath-D can either prevent apoptosis as described under physiological conditions with cath-D knockout mice experiments (Saftig et al., 1995; Koike et al., 2000 Koike et al., , 2003 Nakanishi et al., 2001) , or can promote apoptosis induced by cytotoxic agents (Deiss et al., 1996; Roberg and Ö llinger, 1998; Wu et al., 1998; Ö llinger, 2000; Kagedal et al., 2001; Roberg, 2001; Johansson et al., 2003; Takuma et al., 2003; Emert-Sedlak et al., 2005) . This duality in Catalytically active and -inactive cath-D induce mitochondrial release of cyt c and activation of caspases-9 and -3. (a) Cyt c release. Cells were exposed to 10 mM etoposide for 24 h and cyt c was analysed by immunofluorescence using an anti-rat cyt c mouse monoclonal antibody (dilution 1/50; #556432, BD PharMingen) followed by a RITC-conjugated goat anti-mouse antibody (dilution 1/ 50; Immunotech) as previously described (Johansson et al., 2003) . Bars, 16 mm. (b) Activation of caspases-9 and -3. Cells were exposed to 10 mM etoposide for 24 h and activation of caspases-9 and -3 was analysed by immunofluorescence using respectively an anti-rat cleaved caspase-9 rabbit polyclonal antibody (dilution 1/50; #9507, Cell Signaling) or an anti-rat cleaved caspase-3 rabbit polyclonal antibody (dilution 1/50; #9661, Cell Signaling) followed by a TexasRed-conjugated or FITC-conjugated goat anti-rabbit antibody (dilution 1/100; Jackson Immunoresearch). Bars, 43 mm.
Catalytically inactive cathepsin D enhances apoptosis M Beaujouin et al the role of cath-D in apoptosis is also highlighted by our apparently conflicting results obtained with transfected 3Y1-Ad12 cell lines. Indeed, we previously published that overexpressed cath-D was preventing tumour apoptosis in a manner dependent on its catalytic function in cath-D transfected 3Y1-Ad12 xenografts (Berchem et al., 2002) . Intriguingly, the present study performed with the same cell lines, but treated this time with chemotherapeutic agents, indicates a stimulation of apoptosis independently of cath-D catalytic activity. It seems, therefore, that depending on the environmental conditions, cath-D may either inhibit or promote D231N cath-D (bottom panel) cells were first either pretreated for 1 h with 100 mM Z-VAD-FMK (Calbiochem) or left untreated and were then either left untreated again or were treated with 10 mM etoposide for 24 h. Apoptotic status was analysed and quantified as described in Figure 2c . Bars, 69 mm. *Po0.05 and **Po0.025 versus etoposide for cath-D and   D231N cath-D cells, respectively (t-test). (b) Effect of Z-VAD-FMK on caspase-3 activation. Cath-D cells were either left untreated or were pretreated for 1 h with 100 mM Z-VAD-FMK (Calbiochem) and were then either left untreated again or were treated with 10 mM etoposide for 24 h. Caspase-3 activation was analysed and quantified as described in Figures 4b and 2c , respectively. Bars, 69 mm. *Po0.0025 versus etoposide treatment (t-test).
Catalytically inactive cathepsin D enhances apoptosis M Beaujouin et al apoptosis via different mechanisms. This raises the possibility that this enzyme is involved in more than one apoptotic pathway. However, as pro-apoptotic caspases are unlikely to be directly activated by lysosomal proteases (Cirman et al., 2004) , a critical point in understanding the molecular mechanism of lysosomal-triggered apoptosis is identification of the cellular substrate(s) of cathepsins that could facilitate caspases activation. Our work implicates a role for cath-D independent of its catalytic function both in chemotherapeutic-induced cytotoxicity and in etoposide-induced apoptosis, and we suggest that an adequate strategy to identify cytosolic cath-D interacting protein(s) might be the two-yeast hybrid approach.
